Celldex Therapeutics (CLDX) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Celldex Therapeutics (CLDX) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, gaining 16.1% versus a loss of 18.4%. Over five years, CLDX leads with a -34.1% price change compared with -77.6% for RXRX. Celldex Therapeutics is the larger company by market cap ($2.32 billion vs $2.16 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDX | RXRX |
|---|---|---|
| Share price | $29.55 | $4.04 |
| Market cap | $2.32B | $2.16B |
| 1-day change | -2.91% | -5.50% |
| YTD return | +12.04% | +4.40% |
| 1-year return | +16.06% | -18.36% |
| 5-year return | -34.11% | -77.57% |
| EPS (TTM) | $-4.35 | $-1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54M | — |
| Revenue growth (YoY) | -77.99% | — |
| Net income (latest FY) | $-258.76M | — |
| Gross margin | 87.06% | — |
| Operating margin | -18599.81% | — |
| Net margin | -16748.03% | — |
| 52-week high | $45.14 | $7.18 |
| 52-week low | $22.10 | $2.77 |
| Distance from 52-week high | -34.55% | -43.80% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +113.47% | +78.93% |
| Average volume | 1.27M | 20.56M |
| Shares outstanding | 78.53M | 535.34M |
| Employees | 198 | 600 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLDX has outperformed RXRX by 34.4 percentage points over the past year.
About Celldex Therapeutics
CLDX stock →Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 198 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
CLDX vs RXRX FAQ
Which is bigger, Celldex Therapeutics or Recursion Pharmaceuticals?
Celldex Therapeutics (CLDX) is larger, with a market capitalization of $2.32B compared with $2.16B for Recursion Pharmaceuticals (RXRX).
Which stock has performed better over the past year, CLDX or RXRX?
CLDX returned +16.06% over the past 12 months, compared with -18.36% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are Celldex Therapeutics and Recursion Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Celldex Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Recursion Pharmaceuticals.